Glycokinomics: Emerging Therapeutic Approaches for Malignant Brain TumorsRoger AKroes1* and Joseph R Moskal2
- *Corresponding Author:
- Roger A Kroes
Falk Center for Molecular Therapeutics
Dept. of Biomedical Engineering
Evanston, Illinois, USA
E-mail: [email protected]
Received date: October 29, 2013; Accepted date: November 29, 2013; Published date: November 30, 2013
Citation: Kroes RA, Moskal JR (2013) Glycokinomics: Emerging Therapeutic Approaches for Malignant Brain Tumors. J Glycomics Lipidomics 3:109. doi: 10.4172/2153-0637.1000109
Copyright: © 2013 Kroes RA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The oligosaccharide chains, or glycans, that decorate cell surface glycoproteins and glycolipids are among the most
complex and diverse structures in vertebrate cells. It is estimated the well over half of all human proteins are glycosylated.
Their expression is exquisitely regulated and is the result of the coordinated activity of distinct glycosyltransferases
and glycosyl hydrolases that add or remove individual sugars to complete each glycan chain. Aberrantly expressed
cell surface glycoconjugates are associated with malignant transformation, tumor progression, and metastasis and are
predominantly the result of alterations in their biosynthetic machinery. They mediate key pathophysiological events during
tumorigenesis including altered cellular adhesion and invasivity, molecular trafficking, receptor activation, and intracellular
signal transduction in tumors.